Loading clinical trials...
Loading clinical trials...
The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events....
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
First People's Hospital of Hangzhou
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NCT07627711 · Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, and more
NCT07217717 · Pancreatic Ductal Adenocarcinoma (PDAC)
NCT02600949 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, and more
NCT06921928 · Gastric Cancer, Gastroesophageal Junction Cancer, and more
Hangzhou First People's Hospital
Hangzhou, Zhejiang
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions